PULMONARY TUBERCULOSIS

This study tests new combinations of drugs for adults with lung tuberculosis (TB). The goal is to see if these new regimens work faster and are safer than the current standard treatment. About 315 participants will receive either an experimental drug combo or the usual care for 8…

This Phase 3 trial tests whether adding doxycycline to standard tuberculosis treatment can reduce permanent lung damage and lower the risk of heart problems. Researchers will give 150 adults either doxycycline or a placebo for 8 weeks alongside their TB medication. The main goal …

This study tests whether a new drug called quabodepistat can shorten treatment for drug-resistant tuberculosis (TB) from 6 months to 4 months. About 532 adults and teens with rifampicin-resistant or multidrug-resistant TB will be randomly assigned to receive either the new shorte…

This study tests a new ultra-short treatment for both drug-sensitive and drug-resistant tuberculosis (TB). The goal is to see if a 2-3 month regimen works as well as or better than the standard 4-6 month treatment. About 610 adults with active TB will take part. The approach coul…

This study tests new drug combinations to treat pulmonary tuberculosis (TB) faster than the standard 24-week regimen. About 2500 adults with TB will receive one of several experimental combinations, including two new drugs (BTZ-043 and GSK3036656), for 8 to 16 weeks. Researchers …

This clinical trial is testing new combinations of tuberculosis (TB) drugs to see if they work better than the standard treatment. The study involves 390 adults with newly diagnosed, drug-sensitive TB. Researchers are comparing different drug regimens, including a new drug called…

This study tests whether adding atorvastatin, a widely used cholesterol-lowering drug, to standard tuberculosis (TB) antibiotics can help clear the infection faster and reduce lung damage. About 440 adults with pulmonary TB will receive either standard treatment alone or with dif…

This study tests whether a two-drug HIV regimen (dolutegravir plus lamivudine) works as well as the standard three-drug regimen in people who also have tuberculosis and are on TB treatment. About 150 participants who have never taken HIV medication will be randomly assigned to on…

This study tests whether a smartphone app can tell the difference between a TB cough and other coughs by analyzing audio recordings. Researchers will collect cough sounds from 1,751 people with a cough lasting at least two weeks, then use machine learning to build a quick screeni…

This study aims to find faster, simpler, and cheaper ways to diagnose tuberculosis (TB), a disease that kills over a million people each year. Researchers will test new diagnostic tools on over 26,000 adults in 10 countries who have a cough lasting two weeks or more, or who have …

This Phase 3 trial is testing a new skin test called EEC to see how well it detects tuberculosis (TB) infection in people aged 3 and older. The study will compare EEC to existing tests like EC, TB-PPD, and IGRA in about 1,784 participants, including TB patients, healthy people, a…

This study looks at whether a substance in the blood called soluble PD-1 can help predict if a certain type of lung disease caused by NTM bacteria will get worse. Researchers will follow 500 adults from different countries to see if higher levels of this marker are linked to more…

This study tests whether offering a small cash payment to households can encourage more people to get screened for tuberculosis (TB) in rural Tanzania. Researchers will enroll 360 people recently diagnosed with TB and their families. Half will receive the usual care, and half wil…

This study looks at the bacteria living in the lungs of people with active tuberculosis (TB) and how they change with treatment. Researchers will compare lung bacteria in diseased and healthy areas, and also check the mouth, nose, and gut. They aim to understand how these microbe…

This study will check the lung health of 50 adults who finished treatment for tuberculosis (TB) in Liverpool, UK, about one year after their treatment ended. Participants will take a breathing test and answer questions about their health and wellbeing. The goal is to find out how…